A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Exclusion Criteria

• •Active plasma cell leukemia, or POEMS syndrome.
• •Known, current central nervous system disease involvement.
• •Significant cardiovascular disease.
• •Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent.
• •Radiation therapy within 14 days of study treatment administration.
• •Hematopoietic stem cell transplant within 90 days before the planned start of study treatment or participants with active GVHD disease.
• •Use of any anticancer drug within 14 days before planned start of study treatment.
• •Prior anti-CD47 or anti-SIRP alpha therapy.
• •Participation in other studies involving investigational drug(s) or vaccines within 4 weeks from the last dose
• •Known active, uncontrolled bacterial, fungal, or viral infection.